iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://pubmed.ncbi.nlm.nih.gov/29561882/
Effect of developmental NMDAR antagonism with CGP 39551 on aspartame-induced hypothalamic and adrenal gene expression - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar 21;13(3):e0194416.
doi: 10.1371/journal.pone.0194416. eCollection 2018.

Effect of developmental NMDAR antagonism with CGP 39551 on aspartame-induced hypothalamic and adrenal gene expression

Kate S Collison  1 , Angela Inglis  1 , Sherin Shibin  1 , Soad Saleh  1 , Bernard Andres  1 , Rosario Ubungen  1 , Jennifer Thiam  1 , Princess Mata  1 , Futwan A Al-Mohanna  1
Affiliations

Effect of developmental NMDAR antagonism with CGP 39551 on aspartame-induced hypothalamic and adrenal gene expression

Kate S Collison et al. PLoS One. .

Abstract

Rationale: Aspartame (L-aspartyl phenylalanine methyl ester) is a non-nutritive sweetener (NNS) approved for use in more than 6000 dietary products and pharmaceuticals consumed by the general public including adults and children, pregnant and nursing mothers. However a recent prospective study reported a doubling of the risk of being overweight amongst 1-year old children whose mothers consumed NNS-sweetened beverages daily during pregnancy. We have previously shown that chronic aspartame (ASP) exposure commencing in utero may detrimentally affect adulthood adiposity status, glucose metabolism and aspects of behavior and spatial cognition, and that this can be modulated by developmental N-methyl-D-aspartate receptor (NMDAR) blockade with the competitive antagonist CGP 39551 (CGP). Since glucose homeostasis and certain aspects of behavior and locomotion are regulated in part by the NMDAR-rich hypothalamus, which is part of the hypothalamic-pituitary-adrenal- (HPA) axis, we have elected to examine changes in hypothalamic and adrenal gene expression in response to ASP exposure in the presence or absence of developmental NMDAR antagonism with CGP, using Affymetrix microarray analysis.

Results: Using 2-factor ANOVA we identified 189 ASP-responsive differentially expressed genes (DEGs) in the adult male hypothalamus and 2188 in the adrenals, and a further 23 hypothalamic and 232 adrenal genes significantly regulated by developmental treatment with CGP alone. ASP exposure robustly elevated the expression of a network of genes involved in hypothalamic neurosteroidogenesis, together with cell stress and inflammatory genes, consistent with previous reports of aspartame-induced CNS stress and oxidative damage. These genes were not differentially expressed in ASP mice with CGP antagonism. In the adrenal glands of ASP-exposed mice, GABA and Glutamate receptor subunit genes were amongst those most highly upregulated. Developmental NMDAR antagonism alone had less effect on adulthood gene expression and affected mainly hypothalamic neurogenesis and adrenal steroid metabolism. Combined ASP + CGP treatment mainly upregulated genes involved in adrenal drug and cholesterol metabolism.

Conclusion: ASP exposure increased the expression of functional networks of genes involved in hypothalamic neurosteroidogenesis and adrenal catecholamine synthesis, patterns of expression which were not present in ASP-exposed mice with developmental NMDAR antagonism.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Schematic of experimental design and analysis.
Fig 2
Fig 2
(A) Venn diagram representation of hypothalamic DEGs in ASP, CGP and ASP+CGP groups relative to Control. The numbers marked in the diagram indicate the number of genes significantly up regulated (upward arrows) and down regulated (downward arrows). (B) Top 12 canonical pathways derived from Ingenuity Pathway Analysis in hypothalamus of ASP-exposed mice. The stacked bar chart displays the percentage of genes that were upregulated (red), downregulated (green) and genes not overlapping in dataset (white) in each canonical pathway. Significance level is scored as–log(p-value) from Fischers exact test. The numerical value at the ends of each bar represents the total number of genes in the canonical pathway. CGP denotes developmental NMDAR antagonism with CGP 39551; ASP denotes chronic exposure to aspartame; ASP+CGP denotes chronic aspartame exposure and developmental NMDAR antagonism with CGP 39551.
Fig 3
Fig 3
Functional relationship gene networks representing hypothalamic DEGs in response to (A) ASP exposure (B) developmental antagonism with CGP and (C) ASP + CGP. Red-colored and green-colored gene(s) are up-regulated and down-regulated in the dataset. The intensity of red color reflects the extent of differential expression. Only DEGs with ≥±1.4-fold change relative to CON are depicted, P≤0.05).
Fig 4
Fig 4
(A) Venn diagram representation of adrenal DEGs in ASP, CGP and ASP+CGP groups relative to Control. The numbers marked in the diagram indicate the number of genes significantly up regulated (upward arrows) and down regulated (downward arrows). CGP denotes developmental NMDAR antagonism with CGP 39551; ASP denotes chronic exposure to aspartame; ASP+CGP denotes chronic aspartame exposure and developmental NMDAR antagonism with CGP 39551. Top 12 canonical pathways derived from Ingenuity Pathway Analysis in adrenal glands when exposed to (B) Aspartame (C) developmental antagonism with CGP and (D) ASP + CGP. The stacked bar chart displays the percentage of genes that were upregulated (red), downregulated (green) and genes not overlapping in dataset (white) in each canonical pathway. Significance level is scored as–log(p-value) from Fischers exact test. The numerical value at the ends of each bar represents the total number of genes in the canonical pathway.
Fig 5
Fig 5
Functional relationship gene networks representing adrenal DEGs in response to (A) ASP exposure (B) developmental antagonism with CGP and (C) ASP + CGP. Red and green color indicates upregulation and downregulation of the genes, respectively and intensity of the color reflects the extent of its differential expression. Only DEGs with ≥±1.8-fold change relative to CON are depicted, P≤0.05).
Fig 6
Fig 6. 72 differentially expressed genes common to hypothalamus and adrenal glands were hierarchically clustered and illustrated in a heat map (stringency ≥±1.4 fold change in expression, P<0.05).
Expression levels are represented by a color scale from green (low) to red (high) indicated at the bottom of the heatmap. CGP denotes developmental NMDAR antagonism with CGP 39551. ASP denotes chronic aspartame exposure. ASP+CGP denotes Aspartame exposure and developmental NMDAR antagonism with CGP 39551.
Fig 7
Fig 7
Expression plots of selected genes between RT-PCR and Microarray (A) Steroidogenic Acute Regulator, Star (B) Proopiomelanocortin, Pomc (C) Apolipoprotein A4, Apoa4 (D) Peroxisome Proliferator Activated Receptor Gamma Coactivator 1 Alpha, Ppargc1a (E) Cholinergic Receptor Nicotinic Beta 2, Chrnb2. CON denotes Control; CGP denotes developmental NMDAR antagonism with CGP 39551; ASP denotes chronic exposure to aspartame; ASP+CGP denotes developmental NMDAR antagonism and aspartame exposure. Significance of group against Control is represented as *** at p-value <0.001. (F) Scatter-plot presentation of changes in expression of 13 selected genes as measured by microarray analysis and RT-PCR.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Fitch C, Keim KS; Academy of Nutrition and Dietetics. Position of the Academy of Nutrition and Dietetics: use of nutritive and nonnutritive sweeteners. J Acad Nutr Diet. 2012; 112(5):739–58. doi: 10.1016/j.jand.2012.03.009 - DOI - PubMed
    1. Soffritti M, Padovani M, Tibaldi E, Falcioni L, Manservisi F, Belpoggi F. The carcinogenic effects of aspartame: The urgent need for regulatory re-evaluation. Am J Ind Med. 2014; 57(4):383–97. doi: 10.1002/ajim.22296 - DOI - PubMed
    1. Araújo JR, Martel F, Keating E. Exposure to non-nutritive sweeteners during pregnancy and lactation: Impact in programming of metabolic diseases in the progeny later in life. Reprod Toxicol. 2014; 49:196–201. doi: 10.1016/j.reprotox.2014.09.007 - DOI - PubMed
    1. Azad MB, Sharma AK, de Souza RJ, Dolinsky VW, Becker AB, Mandhane PJ et al. Canadian Healthy Infant Longitudinal Development Study Investigators. Association Between Artificially Sweetened Beverage Consumption During Pregnancy and Infant Body Mass Index. JAMA Pediatr. 2016; 170(7):662–70. doi: 10.1001/jamapediatrics.2016.0301 - DOI - PubMed
    1. Collison KS, Makhoul NJ, Zaidi MZ, Saleh SM, Andres B, Inglis A et al. Gender dimorphism in aspartame-induced impairment of spatial cognition and insulin sensitivity. PLoS One. 2012; 7 (4): e31570 doi: 10.1371/journal.pone.0031570 - DOI - PMC - PubMed

Publication types

MeSH terms

Grants and funding

This study was funded by a grant from the National Science and Technology Innovation Maarifah Program (Grant# MED-13-2506-20). https://www.kacst.edu.sa/eng/about/news/Pages/489.aspx

LinkOut - more resources